



## PRESS RELEASE

Published: 28-05-2021

# Asarina Pharma: Issuance of 700,000 warrants completed

Stockholm, 28 May 2021: **Asarina Pharma AB (publ) today announces that it has issued 700,000 new warrants which have all been acquired by the management and other members of the Asarina staff.**

Each warrant gives the holder the right to subscribe to one new Asarina share at a fixed price of SEK 9.87 (150% of the average share price during the 10 trading days up until and including 18 May 2021). The warrants can be exercised in the second half of 2023. The warrants have been purchased by the Asarina team at a price of SEK 0.53 per warrant.

Peter Nordkild, CEO: "I am delighted that the team members through their personal investment has shown such a strong commitment to our ongoing and future R&D projects. Our next big milestone is obviously the results from the phase IIa study in menstrual migraine."

### **For further information, please contact:**

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: [peter.nordkild@asarinapharma.com](mailto:peter.nordkild@asarinapharma.com)

Jakob Dynnes Hansen, CFO

Phone: +45 5132 3698

E-mail: [jakob.dynnes@asarinapharma.com](mailto:jakob.dynnes@asarinapharma.com)

### **Certified Adviser**

Erik Penser Bank AB

Phone: +46 8-463 83 00

Mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

## **About Asarina Pharma**

We are a Swedish biotech company developing Sepranolone for allopregnanolone-related stress, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA<sub>A</sub> Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.